Pepes Info

Some information about mots c and what it can do.

Peptide per category.

Retatrutide (LY3437943) is an investigational once-weekly, injectable triple-hormone receptor agonist (GIP, GLP-1, and GCG) developed by Eli Lilly for obesity and type 2 diabetes. In trials, it has shown superior weight loss—up to 24.2% over 48 weeks—compared to current therapies, with anticipated FDA approval around 2026.
Key Details and Research Findings
Mechanism: Unlike GLP-1-only drugs (Ozempic/Wegovy) or dual agonists (Mounjaro), retatrutide targets three receptors—GIP, GLP-1, and Glucagon—to increase energy expenditure and reduce appetite.
Weight Loss Efficacy: Phase 2 trials showed up to 24.2% reduction in body weight at 48 weeks.
Diabetes Control: Studies indicate potent HbA1c reductions (up to 2.16% at 36 weeks).

It is a peptide-based, subcutaneous, once-weekly injection.

GHK-Cu (glycyl-l-histidyl-l-lysine) is a naturally occurring, copper-binding tripeptide found in human plasma, saliva, and urine, known for its potent anti-aging, wound-healing, and anti-inflammatory properties. Levels decline with age, leading to its use in skincare for collagen synthesis and hair regrowth. It also shows promise in research for lung protection, reversing cognitive decline, and tissue regeneration.

Typical daily range: 1–2 mg once daily (gradual titration over 12 weeks).